Chemotherapy regimens in early breast cancer: major controversies and future outlookJOERGER, Markus; THÜRLIMANN, Beat.Expert review of anticancer therapy. 2013, Vol 13, Num 2, pp 165-178, issn 1473-7140, 14 p.Article

Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients : A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development GroupJOERGER, Markus; HUITEMA, Alwin D. R; SLEEBOOM, Henk P et al.Clinical cancer research. 2007, Vol 13, Num 21, pp 6410-6418, issn 1078-0432, 9 p.Article

Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients : A Study by the EORTC-PAMM-NDDGJOERGER, Markus; HUITEMA, Alwin D. R; SLEEBOOM, Henk P et al.Clinical pharmacokinetics. 2007, Vol 46, Num 12, pp 1051-1068, issn 0312-5963, 18 p.Article

Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexateJOERGER, Markus; FERRERI, Andrés J. M; KRÄHENBÜHL, Stephan et al.British journal of clinical pharmacology. 2012, Vol 73, Num 2, pp 240-247, issn 0306-5251, 8 p.Article

Management and costs of treating lung cancer patients in a University HospitalDEDES, Konstantin J; SZUCS, Thomas D; BODIS, Stephan et al.PharmacoEconomics (Auckland). 2004, Vol 22, Num 7, pp 435-444, issn 1170-7690, 10 p.Article

Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring: A Pharmacokinetic-Pharmacodynamic Simulation StudyJOERGER, Markus; KRAFF, Stefanie; HUITEMA, Alwin D. R et al.Clinical pharmacokinetics. 2012, Vol 51, Num 9, pp 607-617, issn 0312-5963, 11 p.Article

A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinomaJERMANN, Monika; STAHEL, Rolf A; PLESS, Miklos et al.Cancer chemotherapy and pharmacology. 2006, Vol 57, Num 4, pp 533-539, issn 0344-5704, 7 p.Article

Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumorsJOERGER, Markus; HUITEMA, Alwin D. R; VAN DEN BONGARD, Desiree H. J. G et al.Clinical cancer research. 2006, Vol 12, Num 7, issn 1078-0432, 1951-1953, 2150-2157 [11 p.], 1Article

Germline Polymorphisms in Patients With Advanced Nonsmall Cell Lung Cancer Receiving First-Line Platinum-Gemcitabine Chemotherapy: A Prospective Clinical StudyJOERGER, Markus; BURGERS, Sjaak. A; BEIJNEN, Jos H et al.Cancer. 2012, Vol 118, Num 9, pp 2466-2475, issn 0008-543X, 10 p.Article

Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non-Small-Cell Lung CancerSMIT, Egbert F; BURGERS, Sjaak A; GROEN, Harry J. M et al.Journal of clinical oncology. 2009, Vol 27, Num 12, pp 2038-2045, issn 0732-183X, 8 p.Article

Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patientsJOERGER, Markus; HUITEMA, A. D. R; BOOGERD, W et al.Basic & clinical pharmacology & toxicology (Print). 2006, Vol 99, Num 2, pp 133-140, issn 1742-7835, 8 p.Article

Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapyGAUTSCHI, Oliver; BIGOSCH, Colette; STAHEL, Rolf A et al.Journal of clinical oncology. 2004, Vol 22, Num 20, pp 4157-4164, issn 0732-183X, 8 p.Article